Familial Dysglobulinemia
- Conditions
- Dysglobulinemia
- Interventions
- Genetic: Genetic analysis of peripheral blood samples
- Registration Number
- NCT02853214
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
Multiple Myeloma (MM) is a malignant proliferation of monoclonal plasma cells. Myeloma accounts for almost 14% of all hematologic cancers and is essentially incurable. Myeloma commonly evolves from a precursor disease, Monoclonal gammopathy of undetermined significance (MGUS). Despite intensive study, the etiology of MGUS and myeloma are unknown and no lifestyle or environmental exposure factors have been identified that are consistently linked to increased risk of MM, MGUS or the transition between the two.
The overall goal is to identify risk genes for dysglobulinemia, and more specifically Multiple Myeloma. This will involve the conservation of cells in a bank and genetic sequencing on samples obtained from families with at least two cases of dysglobulinemia. Material used for sequencing is likely to include fresh peripheral blood cells or lymphoblastoid lines established from peripheral blood lymphocytes of patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1868
- 2 cases per family at least
- 1 case alive at least
- biological material available for 1 case at least
- Patients give their informed consent
- attached to the French Health protection service
- Age under 18
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Identification of genetic factors in dysglobulinemia cases Genetic analysis of peripheral blood samples -
- Primary Outcome Measures
Name Time Method Data of a bank cells, clinically annotated, from families with at least 2 cases of dysglobulinemia and at least 1 case alive.plasma cell dysplasia up to 48 months The investigator collects blood samples from patients with dysglobulinemia and their relatives and with this, the investigators constitutes the bank cells thanks to the establishment of lymphoblastoid cell lines.
The investigator considers as "dysglobulinemia" cases patients with Multiple Myeloma, MGUS, Waldenström's disease and MGUS (monoclonal gammopathy of unknown significance ) as wells as plasmacytomas confirmed histologically or cytologically.
- Secondary Outcome Measures
Name Time Method Single Nucleotide Polymorphism array for identification of polymorphisms predictive of dysglobulinemia at day 0 The biological material, obtained from fresh peripheral blood cells and from Lymphoblastoid cells lines, is used for pangenic sequencing. It allows to better understand the mechanism of genetic variations who could be involve in the myeloma genesis
Trial Locations
- Locations (47)
CH de Blois Service d'Hématologie
🇫🇷Blois, France
Service d'hématologie Clinique
🇫🇷Caen, France
CHU Groupe Hospitalier Sud Hématologie Clinique
🇫🇷Amiens, France
CHU Morvan
🇫🇷Brest, France
CHU Albert Michallon
🇫🇷Grenoble, France
CHU de Besançon
🇫🇷Besançon, France
CHU de Chartres
🇫🇷Chartres, France
CHU Amiens Picardie
🇫🇷Amiens, France
CH d'Avignon
🇫🇷Avignon, France
CHU d'Annecy
🇫🇷Metz-Tessy, France
Hématolgie- Hôpital privé Cesson-Sévigné
🇫🇷Cesson-Sévigné, France
Hôpital St Antoine Service des maladies du Sang
🇫🇷Paris, France
Service d'Oncologie Médical, Centre Azuréen de Canrérologie-1
🇫🇷Mougins, France
CHU-HÔTEL -Dieu de Nantes
🇫🇷Nantes, France
CHU de Poitiers
🇫🇷Poitiers, France
Hôpital Avicenne Service d'Hématologie
🇫🇷Bobigny, France
CHU d'ABBEVILLE
🇫🇷Abbeville, France
Service d'Hématologie clinique et Thérapie Cellulaire, CHU de BORDEAUX
🇫🇷Bordeaux, France
CH William Morey, Service d'Hémato-Oncologie
🇫🇷Chalon-sur-Saône, France
Département d'Oncogénitique - Centre Jean Perrin
🇫🇷Clermont-Ferrand, France
Hôpital Sud Francilien
🇫🇷Corbeil-Essonnes, France
Hôpital Saint-Eloi, Département d'Hématologie clinique
🇫🇷Montpellier, France
Centre Hospitalier de Valence
🇫🇷Valence, France
Service d'Oncologie-Radiothérapie - CHU Pointe-à-Pitre/Abymes Guadeloupe
🇫🇷POINTE-à-PITRE, Guadeloupe, France
Hospices Civils de Lyon
🇫🇷Pierre Benite, France
Service de Médecine Interne-Hématologie, CHU de Fort de France Fort de France
🇫🇷Fort-de-France, Martinique, France
Service d'Hématologie Clinique, CHU de Dijon
🇫🇷Dijon, France
Centre Hospitalier de Dunkerque
🇫🇷Dunkerque, France
GHM, Institut Daniel Hollard
🇫🇷Grenoble, France
Service d'Hématologie, CHU de Versailles
🇫🇷Le Chesnay, France
Centre Jean Bernard Clinique Victor Hugo
🇫🇷Le Mans, France
Service d'Onco-hématologie, Hôpital Saint-Vincent GH-ICL
🇫🇷Lille, France
Service des Maladies du Sang CHU Lille
🇫🇷Lille, France
Département d'Oncogénétique, Centre Paoli Calmettes
🇫🇷Marseille, France
CHR-Metz-Thionville, Hôpital de Mercy, Service d'Hématologie
🇫🇷Metz, France
Hôpital de l'Archet 1
🇫🇷Nice, France
CHU Carémeau
🇫🇷Nîmes, France
Hôpital Robert Debré Service du Professeur A. DELMER Hématologie Clinique
🇫🇷Reims, France
CHU de Rennes Hôpital Sud
🇫🇷Rennes, France
Institut Curie
🇫🇷Paris, France
CH de Rodez
🇫🇷Rodez, France
Jean Paul FermandService Immuno-Hématologie Hôpital Saint Louis
🇫🇷Paris, France
Hôpital de Saint- Germain en Laye
🇫🇷Saint-Germain-en-Laye, France
Département d'Hématologie à l'Institut de Cancérologie de la Loire
🇫🇷Saint-Priest-en-Jarez, France
Hôpital Purpan Service d'Hématologie
🇫🇷Toulouse, France
CHU de Nancy, Hôpital de Brabois
🇫🇷Vandœuvre-lès-Nancy, France
Hôpital Privé de Villeneuve d'Ascq
🇫🇷Villeneuve d'Ascq, France